Verici Dx kidney transplant tests use next-generation sequencing to define a personalized, precise risk-profile of each patient over the course of their transplant journey, as well as detecting injury in advance of current clinical and pathological tests.
About Verici Dx
Verici Dx develops tests to understand how a patient will and is responding to organ transplant. One of the most significant threats to a successful transplant, or graft, is the body’s own immune system. Patients’ immune systems differ in how they respond to the presence of the transplanted organ, characterizing this response is called immune phenotyping. Our products and solutions are underpinned by extensive scientific research into the recipient’s immune phenotype and how that impacts on acute rejection, chronic injury and ultimately failure of the transplant. These immuno-profile signatures also inform clinicians as to the optimal strategy for immunosuppression and other therapies for the most successful treatment to ensure graft acceptance with the least amount of side effects.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.
April 14, 2021
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it has entered into a Material Transfer Agreement (“MTA”) with the Icahn School of Medicine at Mount Sinai and Principal Investigator Dr. Peter Heeger, to allow access to samples from the CTOT-19 (Clinical Trials in Organ Transplant1) trial in an […]» Read More
© 2020 VericiDx